JLK

JLK FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of JLK (322510.KQ) as of Nov 3, 2026 is 93.17 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 81.73 % — a change of 14.00% (higher).

FCF Conversion

93.17 %

YoY

14.00%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of JLK is 2025 93.17 % . FCF Conversion Rate (FCF/EBITDA) of JLK was 2024 81.73 % . It decreases by 14.00% higher compared to the previous year.

The JLK FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
72.40 KRW
Jan 1, 2019
63.05 KRW
Jan 1, 2020
282.35 KRW
Jan 1, 2021
99.63 KRW
Jan 1, 2022
92.90 KRW
Jan 1, 2023
92.09 KRW
Jan 1, 2024
81.73 KRW
Jan 1, 2025
93.17 KRW
The JLK FCF Conversion history
YEARFCF ConversionYoY
93.17 %+14.00%
81.73 %-11.24%
92.09 %-0.87%
92.90 %-6.76%
99.63 %-64.71%
282.35 %+347.79%
63.05 %-12.91%
72.40 %+38.24%
52.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

JLK Stock analysis

What does JLK do? JLK, Inc. generates revenue through AI medical analysis solutions, AI industry and security analysis solutions, and AI medical diagnostic platforms. The company's products include AI medical systems, AI quantitative analysis platforms, and AI remote platforms, which are sold to healthcare providers and medical institutions. The primary customer segments are hospitals and clinics seeking advanced diagnostic tools for brain disease detection. Revenue streams are derived from software licensing and subscription services for these AI-driven diagnostic systems. JLK, Inc. focuses on developing AI-based data-driven diagnostic systems specifically for brain disease detection. The company's AI medical diagnostic platforms are designed to provide accurate and efficient analysis for medical professionals. These platforms are part of the broader suite of AI medical analysis solutions that include AI quantitative analysis and AI remote platforms. The firm's target market includes healthcare facilities requiring cutting-edge technology for neurological diagnostics. The company's software products, such as AI medical systems and AI quantitative analysis platforms, are marketed to healthcare institutions for integration into their diagnostic workflows. Revenue is primarily generated through licensing agreements and recurring subscription fees for access to the AI-driven diagnostic tools. These solutions are positioned as essential for modern healthcare providers aiming to enhance diagnostic accuracy and patient outcomes in brain disease detection. JLK is one of the most popular companies on Eulerpool.

Frequently Asked Questions about JLK stock

FCF Conversion Rate (FCF/EBITDA) of JLK is 93.17 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of JLK changed from 81.73 % to 93.17 %, representing a 14.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) JLK since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s JLK with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — JLK

All Key Metrics — JLK